Active substances set

Search phrase: gemtuzumab ozogamicin

Below you will find a list of active substances registered by the European Medical Agency (EMA) in the last 15 years, recommended by the European Society of Clinical Oncology (ESMO) and their reimbursement status in the country.

Acute myeloid leukemia

Gemtuzumab ozogamicin	Gemtuzumab Ozogamicin is indicated for combination therapy with daunorubicin (DNR) and cytarabine (AraC) for the treatment of patients aged 15 years and above with previously untreated, de novo CD33-positive acute myeloid leukaemia (AML), except acute promyelocytic leukaemia (APL).	REIMBURSEMENT WITH RESTRICTIONS ESMO